Current development of the second generation of mTOR inhibit…
Well Cited
112
Citations110
Refs2011
Year
Search Works
Work Details
- DOI 10.5732/cjc.011.10281
- PMID https://pubmed.ncbi.nlm.nih.gov/22059905
- OpenAlex ID W2032082659
- Type Article
- Language EN
- Published 08 Nov 2011
- Volume 32 (5)
- Pages 8–18
- Source 癌症:英文版
- FWCI 2.12
- Countries 1
- Institutions 3
- Added 10 Oct 2025
- Updated 16 Oct 2026
External Links
MENU
0
Current development of the second generation of mTOR inhibitors as anticancer agents
Article 2011 EN Bronze
The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a "master switch" for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and thus, mTOR has emerged as an important target for the design of anticancer agents. mTOR is found in…
112
Citations
110
References
2
Authors
2.12
FWCI
Citations by Year
Last 14 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
2 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Hongyu Zhou | Louisiana State University Hea… (US) | |
| 2 | Shile Huang | Louisiana State University (US) Feist-Weiller Cancer Center (US) +1 |
Related Works
10Data: OpenAlex